Related Experiment Video
Updated: Jun 6, 2025

Involving Individuals with Developmental Language Disorder and Their Parents/Carers in Research Priority Setting
Published on: June 6, 2020
Lp(a): A Rapidly Evolving Therapeutic Landscape
Khalil Anchouche1,2, George Thanassoulis3,4
1McGill University Health Centre and Research Institute, Montréal, Québec, Canada.
Insights
Novel therapies targeting elevated lipoprotein(a) (Lp[a]) are in development. These promising treatments aim to lower Lp[a] levels, addressing a significant, unmitigated cardiovascular risk factor.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Genetics
Background:
- Elevated lipoprotein(a) (Lp[a]) is a genetically determined risk factor for atherosclerotic coronary artery disease and aortic stenosis.
- Lp[a] is prevalent, prompting recommendations for universal adult screening.
- Currently, no specific Lp[a]-lowering drugs are approved for clinical use.
Purpose of the Study:
- To review emerging Lp[a]-lowering therapies in the drug development pipeline.
- To discuss the potential future clinical applications of these novel treatments.
Main Methods:
- Review of ongoing phase 3 clinical trials for novel Lp[a]-lowering therapies.
- Description of RNA-based therapies targeting LPA mRNA degradation.
- Overview of early-stage drug development candidates.
Main Results:
- Pelacarsen and olpasiran are RNA-based therapies in phase 3 trials, degrading LPA mRNA.
- Other candidates like Lepodisiran, Zerlasiran, and Muvalaplin are in early development.
- No Lp[a]-lowering drugs are currently approved, but promising candidates are under investigation.
Conclusions:
- Novel RNA-based therapies show promise for lowering lipoprotein(a).
- Successful clinical trials could provide the first treatments for this cardiovascular risk factor.
- These therapies may significantly expand cardiovascular care options.
Purpose Of Review:
Elevated lipoprotein(a) (Lp[a]) is a genetically determined cardiovascular risk factor, causally linked to both atherosclerotic coronary artery disease and aortic stenosis. Elevated Lp(a) is widely prevalent, and several cardiovascular societies now recommend performing Lp(a) screening at least once in all adults. However, there are currently no approved drugs aimed specifically at lowering Lp(a). In this review, we describe several promising Lp(a)-lowering therapies in the drug development pipeline and outline what role these may have in future clinical practice.
Recent Findings:
Pelacarsen and olpasiran are two novel RNA-based injectable therapies which are being studied in ongoing phase 3 clinical trials, with the earliest of these to be concluded in 2025. These drugs act by degrading transcribed LPA mRNA, which would normally yield the apolipoprotein(a) constituent of Lp(a). Other candidate drugs, such as Lepodisiran, Zerlasiran, and Muvalaplin, are also in early-stage development. While there are presently no Lp(a)-lowering drugs available for routine clinical use, several promising candidates are currently under investigation. If these prove to be effective in randomized clinical trials, they will expand the cardiovascular care armamentarium and will allow clinicians to treat a presently unmitigated cardiovascular risk factor.
Related Concept Videos
Drug Therapy
Antianxiety Medications
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Psychotherapy
Healthcare Agencies II
Parish nursing is a growing specialty nursing profession that focuses on holistic healthcare, health promotion, and illness prevention. It blends professional nursing practice with a health ministry, focusing on health and healing within the context of a Christian community. Parish nurses serve as health educators, referral sources,...
Local Anesthetics: Clinical Application as Epidural Anesthesia
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Local Anesthetics: Pharmacokinetics

